Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer

Basit Öğe Kaydı
dc.contributor.authorKaracin, Cengiz
dc.contributor.authorSunar, Veli
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorYilmaz, Ali
dc.contributor.authorAyhan, Murat
dc.contributor.authorErsoy, Mustafa
dc.contributor.authorGuven, Deniz Can
dc.date.accessioned2024-04-24T17:18:41Z
dc.date.available2024-04-24T17:18:41Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.en_US
dc.identifier.doi10.2217/fon-2023-0763
dc.identifier.endpage214en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue4en_US
dc.identifier.pmid38328890
dc.identifier.scopus2-s2.0-85185827749
dc.identifier.scopusqualityQ2
dc.identifier.startpage207en_US
dc.identifier.urihttps://doi.org/10.2217/fon-2023-0763
dc.identifier.urihttps://hdl.handle.net/11468/18869
dc.identifier.volume20en_US
dc.identifier.wosWOS:001157671000001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofFuture Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectLow Gradeen_US
dc.subjectOvarian Canceren_US
dc.subjectPeritoneumen_US
dc.subjectSerousen_US
dc.subjectTubaen_US
dc.titleEfficacy and safety of bevacizumab in patients with low-grade serous ovarian canceren_US
dc.titleEfficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu